CKD prevalence in Africa is estimated at 13-16%, driven by hypertension, diabete...
Africa Trials
46
US Trials
1,759
Gap Ratio
38x
Nations
54
Key Finding
Africa hosted 46 chronic kidney disease trials versus 1,759 in the United States, a 38-fold disparity in research investment.
Regional Comparison
Distribution Analysis
Inequality Profile
Temporal & Structural
Why It Matters
CKD prevalence in Africa is estimated at 13-16%, driven by hypertension, diabetes, and HIV nephropathy, yet renal trial investment is negligible and dialysis access is under 5%.
The Evidence 140 words · target 156
In the burden-versus-investment landscape of African health research, does the distribution of chronic kidney disease trials across African nations reveal a systematic research gap? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation. Africa hosted 46 chronic kidney disease trials (0.2% of its portfolio) compared to 1,759 in the United States, yielding a 0.0-fold disparity in per-population investment. Temporal analysis showed 17.1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted. These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa. Interpretation is limited by reliance on ClinicalTrials.gov alone, which may undercount locally registered African studies.
Sentence Structure
Question
In the burden-versus-investment landscape of African health research, does the distribution of chronic kidney disease trials across African nations reveal a systematic research gap?
Dataset
This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.
Method
gov through April 2026.
Primary Result
Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation.
Robustness
Africa hosted 46 chronic kidney disease trials (0.
Interpretation
2% of its portfolio) compared to 1,759 in the United States, yielding a 0.
Boundary
0-fold disparity in per-population investment.
Extra
Temporal analysis showed 17.
Extra
1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted.
Extra
These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa.
Extra
Interpretation is limited by reliance on ClinicalTrials.
Extra
gov alone, which may undercount locally registered African studies.